Highlights
- Third quarter Revenue was USD 13,832 thousand, down 6% from USD 14,690 thousand.
- The net loss was USD 14,163 thousand, or USD 0.52 per share.
- Cash and cash equivalents were USD 58,746 thousand at September 30, 2026.
- Nine-month revenue rose to USD 44,306 thousand from USD 40,627 thousand.
CVRx, Inc. (NASDAQ:CVRX) shares were trading near their all-time low at USD 0.87 on November 6, 2026, down 41.07% on the day. The company reported third quarter revenue of USD 13,832 thousand and a net loss of USD 14,163 thousand, or USD 0.52 per share.
CVRx is a commercial-stage medical device company focused on minimally invasive neuromodulation solutions for patients with cardiovascular disease. Its proprietary platform technology is Barostim.
Third Quarter Results
Revenue was USD 13.8 million, a decrease of USD 0.9 million, or 6%, from the third quarter of 2025. Gross Profit was USD 11,998 thousand against USD 12,753 thousand.
Total operating expenses were USD 25,043 thousand against USD 25,021 thousand. The loss from operations was USD 13,045 thousand against USD 12,268 thousand. The net loss was USD 14,163 thousand against USD 12,870 thousand, and the loss per share was USD 0.52 against USD 0.49.
Nine-Month Results
For the nine months ended September 30, 2026, revenue was USD 44,306 thousand against USD 40,627 thousand. Gross profit was USD 38,603 thousand against USD 34,515 thousand, and total operating expenses were USD 76,832 thousand against USD 74,596 thousand.
The loss from operations was USD 38,229 thousand against USD 40,081 thousand. The net loss was USD 41,327 thousand, or USD 1.55 per share, against USD 41,372 thousand, or USD 1.59 per share.
Coverage Development
On July 17, 2026, Devoted Health issued a Medicare Advantage coverage policy for Barostim therapy. The filing describes Devoted Health as a national health insurer with the eighth largest Medicare Advantage enrollment in the United States.
Cash, Financing and Balance Sheet
Cash and cash equivalents were USD 58,746 thousand against USD 75,708 thousand at December 31, 2025. Net cash used in Operating Activities was USD 31,887 thousand for the nine months against USD 30,412 thousand. Net cash provided by financing activities was USD 15.3 million against USD 10.1 million.
Total Assets were USD 87,612 thousand against USD 104,794 thousand. Total liabilities were USD 73,794 thousand against USD 65,470 thousand, and total stockholders' Equity was USD 13,818 thousand against USD 39,324 thousand. The accumulated Deficit was USD 631,979 thousand.
The filing records a full valuation allowance against deferred tax assets. There were 28,485,019 shares outstanding as of October 29, 2026.






Please wait processing your request...